Hutson, T.E., Lesovoy, V., Al-Shukri, S., Stus, V.P., Lipatov, O.N., Bair, A.H., Rosbrook, B., Chen, C., Kim, S. and Vogelzang, N.J. (2013) Axitinib versus Sorafenib as First-Line Therapy in Patients with Metastatic Renal-Cell Carcinoma: A Randomised Open-Label Phase 3 Trial. Lancet Oncology, 14, 1287-1294.
http://dx.doi.org/10.1016/S1470-2045(13)70465-0

has been cited by the following article:

• TITLE: Efficacy and Safety of Axitinib as First-Line Therapy in Japanese Patients with Metastatic Renal Cell Carcinoma

  AUTHORS: Takeshi Namekawa, Satoshi Fukasawa, Atsushi Komaru, Masayuki Kobayashi, Takayuki Ohzeki, Yosuke Sato, Junryo Rii, Hirotsugu Uemura, Tomohiko Ichikawa, Takeshi Ueda

  KEYWORDS: Axitinib, Renal Cell Carcinoma, First Line

  JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.8, July 28, 2015

  ABSTRACT: Previous study reported that patients treated with axitinib as second-line therapy had longer median progression-free survival than those treated with sorafenib for metastatic renal cell carcinoma (mRCC). In this study, we reviewed our experience of axitinib as a first-line therapy for mRCC in Japanese patients, focusing on its efficacy and safety. We retrospectively assessed 26 patients treated with axitinib as a first-line therapy for mRCC from July 2010 to July 2014 at Chiba Cancer Center and Kinki University Hospital. Observation period was 24.6 ± 18.3 months. The objective response rate was 50.0%, and the median progression-free survival was 27.5 months. Overall survival was not estimable. Common grade 3 adverse events were hypertension in 19 patients and proteinuria in 5 patients. Axitinib demonstrated significant efficacy as a first-line therapy in Japanese patients with mRCC. Careful monitoring and management of the adverse effects may help to control its toxicities.